Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharm-OUD-Care: Physician-Pharmacist Collaboration for OUD
NCT03248947Phase 1Completed
- Sponsor
- Duke University
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buprenorphine + naloxone in opioid use disorder (OUD), sponsored by Duke University. Primary endpoints: Recruitment Rate up to 6 months, Treatment Retention up to 6 months and 2 more. Started Mar 2018; status: completed.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03248947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248947.